Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Arthritis Rheumatol. 2019 Dec 10;72(2):262–272. doi: 10.1002/art.41074

Figure 3: IgG in rheumatoid arthritis targets peptides with amino acids associated with intrinsic disorder.

Figure 3:

Peptides were grouped by the number of specific amino acids present and the average binding for all rheumatoid arthritis subjects divided by controls was plotted for each peptide group. Results are shown for amino acids in native peptides (n=95,761) that demonstrated a real increase (A) or reduction (B) in IgG binding or (C) a real increase in IgG binding for citrulline-containing peptides (n=35,459) in rheumatoid arthritis as compared to controls with increasing number of that amino acid. The difference in binding was evaluated by a t test for each peptide group compared to peptides in which that amino acid was not present (i.e. the 0 group) or, in the case of citrulline-containing peptides, compared to a single citrulline present (i.e. the 1 group). For all panels: trend line in red, n=48 rheumatoid arthritis subjects and 12 controls, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.